If I didn't own so much now, I think I would be buying too,,,congrats on the shares today,,
I got in around ,40 and just hoping to see a pop to around ,50 and decide what to do then.
Then where are the buyers???...you are a one man band..trying to play every
instrument and keep the batons in the air,,,not doing a bad job either.
Tell me where are the buyers, appreciate your enthusiasm but that doesn't make a
the PPS go up,,,,in fact, it continues to decline, why? Give me one explanation for
the steady decline
HEB just needs to perform, all this silly talk will subside when there are verifiable
test results, and analysts start to cover this company..until then, the banter will continue.
Your intuition may be more accurate than you thought,,,I hope so anyway...
You may want to buy some before it hits .63, may be sooner than you think..
Arrowhead is initiating coverage on Hemispherx Biopharma
Inc. with a fair value bracket of $1.67 in the low bracket and
$2.79 in the high bracket scenario using the Discounted Cash
Flow (DCF) Valuation Method.
Key Highlights: (1) Alferon N Injection® presents a huge
growth potential for the Company due to growing number of
patients in US suffering from genital warts, a common clinical
manifestation of HPV infection;(2) Further, Alferon N
Injection® is the only natural interferon approved by FDA for
marketing in the US and hence the Company enjoys a
favorable competitive position; (3) The Company is
conducting work, based on published studies, on the potential
use of natural killer cell levels and activity to act as a
biomarker for CFS, which if positive could facilitate approval
of Ampligen® for CFS.;(4) Alferon® & Ampligen® are also
good candidates for treatment of Ebola as they have
demonstrated broad anti-viral efficacy. Further, studies
indicate that nasally-delivered Ampligen® plus an intranasal
seasonal influenza vaccine induces cross-reactive antibody
formation against Avian H5N1 and H7N9 Influenza HA in
humans (5) The Company has invested more than $7.5MM to
upgrade the Alferon manufacturing facility and the
management expects this facility to be approved in
approximately one year from now; (6) The Company has
formed a strategic partnership with Armada Healthcare for
the distribution & marketing
Hemispherx Biopharma, Inc. (HEB) of the Healthcare sector (Biotechnology) has gained 2.00% per share early this morning. Hemispherx Biopharma, Inc. (HEB) traded at $0.24 with a market cap of 048, volume of 094,558 shares, a weekly performance of 5.480% and EPS growth this year of 16.70%. Hemispherx Biopharma, Inc. (HEB)’S monthly performance stands at – 2.960% and Hemispherx Biopharma, Inc. (HEB) is a stock to watch with an analyst rating of 2.00 (Scale = 5 Strong Sell – 3 Neutral – 1 Strong Buy)
News is the only thing that launch this stock to new highs,,just noise until then.
I need to quit watching this if there is no news in the morning, rarely is news released
later in the day. Check in the morning for news, and later in the day to see how it finished.
That is my "new years resolution"...twice a day, and live life!